The label expansion unlocks a younger patient segment for ASCENIV, which could drive volume growth in coming quarters. Monitor upcoming quarterly reports for initial prescription trends and any commentary on manufacturing capacity to meet incremental demand.
Price Chart
Executive Summary
ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune compromised patients aged 2 and older, up from the previous age restriction of 12+. This fulfills a post-marketing commitment and significantly expands the addressable patient population for the company's lead IVIG product.
Key Facts
- FDA approved label expansion for ASCENIV to include pediatric patients 2 years and older with primary humoral immunodeficiency
- Previously ASCENIV was indicated only for patients aged 12 and older
- Approval represents completion of the post-marketing pediatric study commitment
- ASCENIV is ADMA's key plasma-derived IVIG product, originally approved in 2019
Financial Impact
Expands addressable patient population for ASCENIV from PI patients aged 12+ to those aged 2+, potentially increasing revenues. No specific financial guidance or revenue contribution provided in the filing.
Risk Factors
- Competition from other IVIG products in the pediatric PI market
- Manufacturing constraints if demand increases significantly
- Potential safety or tolerability issues in younger children not fully captured in trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-018667 |
| Document: ef20072196_ex99-1.htm | 0001140361-26-018667 |
| Document: 0001140361-26-018667-index-headers.html | 0001140361-26-018667 |
| Document: 0001140361-26-018667-index.html | 0001140361-26-018667 |
| Document: 0001140361-26-018667.txt | 0001140361-26-018667 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $10.73 | awaiting T+60 | — | $11.06 (+3.12%) |
Aug 8, 2026 11w ago | Institutional Cluster | $9.75 | awaiting T+60 | — | $11.06 (+13.49%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.21 $9.54 | ▲ +16.20% | ▲ +12.94% | $11.06 (+34.77%) |
May 4, 2026 25w ago | 8-K | $10.31 $8.71 | ▼ −15.52% | ▼ −17.38% | $11.06 (+7.32%) |
Apr 15, 2026 27w ago | DEFA14A | $10.74 $8.97 | ▼ −16.48% | ▼ −23.53% | $11.06 (+3.03%) |
Mar 27, 2026 30w ago | Press Release | $9.25 $8.72 | ▼ −5.78% | ▼ −21.85% | $11.06 (+19.62%) |
Feb 25, 2026 34w ago | 8-K | $15.18 $8.46 | ▼ −44.27% | ▼ −52.02% | $11.06 (−27.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers